…Background Gastrointestinal disorders are common worldwide and impose substantial socioeconomic burde…
Browse by entity family
An entity family is a category of extracted information. Choose one to browse its named entities and supporting articles.
Organisations named as supporting, sponsoring, or funding research.
5,089 articles · 9,137 mentionsInstitutionsUniversities, hospitals, research centres, networks, and public bodies.
11,350 articles · 22,378 mentionsDrugsNamed medicines, compounds, vaccines, and pharmacological agents.
10,506 articles · 58,393 mentionsDiseasesNamed diseases, disorders, syndromes, injuries, and health conditions.
23,712 articles · 125,551 mentionsTreatmentsClinical therapies and care approaches used to manage a condition.
7,227 articles · 16,644 mentionsInterventionsProgrammes, procedures, policies, and other actions being evaluated.
4,132 articles · 9,994 mentionsClinical instrumentsNamed questionnaires, scales, scores, indices, and other clinical outcome assessments.
945 articles · 1,957 mentionsPopular entities in these results
Choose an entity to see the articles in which it was identified.
Matching articles
29,499 articles · page 54 of 2459…easingly recognized as a key contributor to the pathogenesis of Irritable Bowel Syndrome (IBS), influencing intestinal permeability, immune activation, …
…59/81 (72.8%) (AO)/43/327 (13.1%) and 55/327 (16.8%) (NRI) with adalimumab. Initial non-responders/incomplete responders benefited from sw…
… to ArLD (AAPC 3.28), liver cancer due to HepB (AAPC 3.17), and liver cancer due to HepC (AAPC 3.14). In regard to the ASDR, a statistically…
…he ongoing OLE. PRO-C3 correlates well with established NITs in PBC, therefore serving as a potentially useful marker of disease pr…
…pared with those with FTLB alone. Better clinical screening for autism is essential in patients with FTLB as DAWBA is insufficient.…
…on, IFN-γ production, or activation marker expression. In vivo, BLINA monotherapy significantly reduced leukemia burden, but resulted…
… (IQR 84–1184) and median LV ejection fraction 56% (IQR 48–60). MINOCA terminology was documented in medical records for 37/97 patient…
…and a non-vitamin K antagonist OAC. In this patient population, clopidogrel is the P2Y12 inhibitor of choice given the significantly lower …
…firmed in 31 patients (PPV 62%), including 20 with HFrEF. Using NT-proBNP alone, efficiency was limited: 1.61 TTEs per confirmed HF and 2…
…1), LVAD procedure during hospitalization (aOR 0.204, p<0.001), peripheral vascular disease (aOR 0.875, p=0.013), obesity (aOR 0.776, p<0.001), alcohol abu…
…en male (70.2% vs. 29.8%, p<0.05), and were more likely to have ischaemic heart disease (23.6% vs. 14.7%, p<0.05) and type 2 diabetes mellitus (20.3% v…